Literature DB >> 32735833

Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.

Maria-Victoria Mateos1, Saad Z Usmani2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32735833     DOI： 10.1016/S2352-3026(20)30188-5

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  2 in total

Review 1.  Antibody-Based Treatment Approaches in Multiple Myeloma.

Authors:  Hitomi Hosoya; Surbhi Sidana
Journal:  Curr Hematol Malig Rep       Date:  2021-03-17       Impact factor: 3.952

2.  Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Authors:  Enriqueta Felip; Mauricio Burotto; Zanete Zvirbule; Luis A Herraez-Baranda; Pascal Chanu; Smita Kshirsagar; Vidya Maiya; Phyllis Chan; Emanuela Pozzi; Mathilde Marchand; Marion Monchalin; Kunihiko Tanaka; Nadia Tosti; Bei Wang; Eleonora Restuccia
Journal:  Clin Pharmacol Drug Dev       Date:  2021-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.